Why Radiopharm Theranostics Limited’s (RADX) Stock Is Down 5.27%
As of Wednesday, June 03, Radiopharm Theranostics Limited’s RADX share price has dipped by 5.27%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: Radiopharm Theranostics Limited (RADX)
Radiopharm Theranostics Limited RADX
$1.08
-0.04
-3.26%
October 30, 2026 12:34:36 PM
EST
Volume: 8,923
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Commentary & Analysis
Why Radiopharm Theranostics Limited’s (RADX) Stock Is Down 6.95%
As of Tuesday, May 19, Radiopharm Theranostics Limited’s RADX share price has dipped by 6.95%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Radiopharm Theranostics Limited’s (RADX) Stock Is Down 5.30%
As of Friday, March 20, Radiopharm Theranostics Limited’s RADX share price has dipped by 5.30%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Radiopharm Theranostics Limited’s (RADX) Stock Is Up 7.07%
As of Friday, March 06, Radiopharm Theranostics Limited’s RADX share price has surged by 7.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Radiopharm Theranostics Limited’s (RADX) Stock Is Up 6.47%
As of Friday, January 09, Radiopharm Theranostics Limited’s RADX share price has surged by 6.47%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | RADX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.3 | $226.9 | 9% |
|
| Shares Out (Mil) | 2,475.6 | 53.4 | 98% |
|
| Institutional Ownership | 63.6% | 92.9% | 40% |
|
| Float (Mil) | 3,589.3 | 40.7 | 97% |
|
| Beta | 0.86 | 0.95 | 51% |
|
| Avg Daily Volume (000s) | 22 | 469 | 22% |
|
| Price Change (52-week) |
(79.5%) | 46.6% | 9% |
|
| Growth | RADX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (150.4%) | (10.1%) | 1% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RADX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9 | $37 | 8% |
|
| Net Income (TTM) (Mil) | ($39) | ($44) | 18% |
|
| EPS (TTM) | ($0.013) | ($1.600) | 38% |
|
| Operating Cash Flow (TTM) (Mil) | ($37) | ($33) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($17) | $2 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $14 | $174 | 9% |
|
| Valuation | RADX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | RADX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (266.9%) | 65.6% | 1% |
|
| Net Margin | (442.7%) | (71.5%) | 2% |
|
| ROA | (80.2%) | (47.1%) | 7% |
|
| ROE | (169.7%) | (53.0%) | 5% |
|
| Liabilities to Assets | 62.9% | 29.6% | 58% |
|
| F-Score | 2 | 2 | 7% |
|
Radiopharm Theranostics Limited did not pass any screens on 10/30/2026.
